Iovance Biotherapeutics, INC.

Development and commercialization of immunotherapies

Based in CA

🤖

AI Overview

With $420K in lobbying spend across 12 quarterly filings, Iovance Biotherapeutics, INC is an active lobbying client. Their lobbying covers 1 issue area. Active from 2020 to 2023.

$420K
Total Spend
4
Years Active
1
Firms Hired
2
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2020$30K
2021$190K
2022$200K
2023$0

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid

  • Education around tumor infiltrating lymphocytes (TIL) cancer therapies
  • Education around tumor infiltrating lymphocytes (TIL) cancer therapies;
  • H.R. 133, Consolidated Appropriations Act, 2021 (Public Law 116-260)
  • Education around tumor infiltrating lymphocytes (TIL) cancer therapies;
  • H.R. 1319, American Rescue Plan Act of 2021 (PL 117-2);
  • Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116
  • Education around tumor infiltrating lymphocytes (TIL) cancer therapies;
  • Implementation of American Rescue Plan Act of 2021 (PL 117-2);
  • Continued monitoring of Consolidated Appropriations Act, 2021

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.